Recent News

• 04.01.2026 - TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
• 03.23.2026 - Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers
• 02.27.2026 - TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
• 02.24.2026 - TuHURA Biosciences Announces Participation in Upcoming Investor Conferences
• 02.17.2026 - TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers
• 02.12.2026 - TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 02.02.2026 - TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma
• 12.15.2025 - TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
• 12.11.2025 - TuHURA Biosciences Provides Corporate Update Following Recent Financing

Recent Filings

• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2026 - 8-K Current report
• 01.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.08.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.17.2025 - 4 Statement of changes in beneficial ownership of securities